Verum Diagnostics Inc

medical devices

About

Verum Diagnostics Inc (Verum) discovers and commercializes biomarkers for the detection, prediction and treatment of clinically important conditions in women's health and gastrointestinal disorders. These include PROM (Premature Rupture of Membranes), preeclampsia, early and pregnancy loss. The Amnio100 PROM test is our lead indication. Globally preterm birth is among the most frequent causes of death among neonates within the first month of life. The Amnio100 has shown a significantly higher performance (100% specificity and 100% sensitivity) compared to existing PROM tests when tested on several thousand clinical samples. It will change the current PROM clinical management approach when introduced into the market. Verum is open to discussing scientific, regulatory, and commercial strategic relationships to advance its programs.

Technologies

Bootstrap Framework Google Font API WordPress.org Apache Mobile Friendly Remote

Keywords

biotech biomarkers pregnancy appendicitis prom premature rupture of membranes diagnostics early pregnancy loss preeclampsia point of care medical equipment manufacturing rapid screening b2c biomarker-based testing diagnostic biomarkers biotech industry healthcare equipment & supplies diagnostic tests clinical outcomes point-of-care testing healthcare technology biotech management operational efficiency healthcare biomarker in amniotic fluid medical equipment and supplies manufacturing accurate diagnostics predictive biomarkers biotech innovation disruptive technology

Location

Atlanta, Georgia, United States

Related Companies

Companies in the same industry